title: Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
abstract: OBJECTIVE
  The present study was designed to explore the clinical values of microRNA-129 (miR-129) expression in peripheral blood mononuclear cells for prostate cancer patients and the role of miR-129 in the proliferation of prostate cancer.
  
  
  METHODS
  The peripheral blood mononuclear cells were isolated form blood simple from 98 patients confirmed with prostate cancer and 56 matched healthy volunteers. Reverse transcription quantitative real-time polymerase chain reaction (qRT-PCR) was employed to determine the expression level of miR-129 in peripheral blood mononuclear cells. Cox proportional hazards regression models and Kaplan-Meier analysis were used to evaluate the association of miR-129 expression with clinical and pathological characteristics of prostate cancer patients. The effect of miR-129 on the proliferation of prostate cancer cells in vitro was also determined.
  
  
  RESULTS
  Reverse transcription quantitative real-time polymerase chain reaction (qRT-PCR) results showed that the expression of miR-129 was dramatically down-regulated in peripheral blood mononuclear cells for prostate cancer patients in comparison with healthy controls (P<0.05). The decrease in miR-129 expression in peripheral blood mononuclear cells was significantly associated with aggressive clinical pathological features such as histological grade (P=0.010), high preoperative PSA level (P=0.002), pathological stage (P=0.011), high Gleason score (P=0.005), lymph node metastasis (P=0.002), angiolymphatic invasion (P=0.004), biochemical recurrence (P=0.001). The prostate cancer patients with a low miR-129 expression in peripheral blood mononuclear cells had an obviously shorter BCR-free survival compared with high miR-129 expression (P<0.001). The Cox multivariate analysis established that the miR-129 expression may be an independent prognostic factor for biochemical recurrence (BCR)-free survival prostate cancer patients (P=0.000). The results of in vitro CCK-8 assays, as well as proliferating cell nuclear antigen (PCNA) and phosphorylated histone-3 (P-H3) (markers of proliferation) indicated that miR-129 overexpression markedly retarded the proliferation of PC-3 and DU-145 cells.
  
  
  CONCLUSIONS
  Our results provide the first evidence that the miR-129 is significantly downregulated in prostate cancer patients and multivariate analysis confirmed that miR-129 is a novel independent prognostic factor for prostate cancer. Overexpression of miR-129 exerts tumor suppressive functions and abrogates prostate cancer growth.
authors.affiliation: Department of Urology, Jinling Hospital, School of Medicine, Nanjing University Nanjing 210002, Jiangsu, China.
authors.forename: Song
authors.initials: S
authors.lastname: Xu
authors.affiliation: Department of Urology, Jinling Hospital, School of Medicine, Nanjing University Nanjing 210002, Jiangsu, China.
authors.forename: Xiao-Ming
authors.initials: XM
authors.lastname: Yi
authors.affiliation: Department of Urology, Jinling Hospital, School of Medicine, Nanjing University Nanjing 210002, Jiangsu, China.
authors.forename: Wen-Quan
authors.initials: WQ
authors.lastname: Zhou
authors.affiliation: Department of Urology, Jinling Hospital, School of Medicine, Nanjing University Nanjing 210002, Jiangsu, China.
authors.forename: Wen
authors.initials: W
authors.lastname: Cheng
authors.affiliation: Department of Urology, Jinling Hospital, School of Medicine, Nanjing University Nanjing 210002, Jiangsu, China.
authors.forename: Jing-Ping
authors.initials: JP
authors.lastname: Ge
authors.affiliation: Department of Urology, Jinling Hospital, School of Medicine, Nanjing University Nanjing 210002, Jiangsu, China.
authors.forename: Zheng-Yu
authors.initials: ZY
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D019540:Area Under Curve; D014408:Biomarkers, Tumor / Q000097:blood* / Q000235:genetics; D016022:Case-Control Studies; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D016009:Chi-Square Distribution; D018572:Disease-Free Survival; D015536:Down-Regulation; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D007963:Leukocytes, Mononuclear / Q000378:metabolism*; D008297:Male; D035683:MicroRNAs / Q000097:blood* / Q000235:genetics; D008875:Middle Aged; D015999:Multivariate Analysis; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D011471:Prostatic Neoplasms / Q000097:blood* / Q000235:genetics / Q000473:pathology / Q000628:therapy; D012372:ROC Curve; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012307:Risk Factors; D014162:Transfection
chemical_list: D014408:Biomarkers, Tumor; D035683:MicroRNAs; C541915:Mirn129 microRNA, human
keywords: miR-129; peripheral blood mononuclear cells; prognosis; proliferation; prostate cancer
references.citation: PLoS One. 2013;8(8):e72400
references.pmid: 23951320
references.citation: Liver Int. 2013 Mar;33(3):476-86
references.pmid: 23402613
references.citation: Biochem Biophys Res Commun. 2015 Aug 14;464(1):161-7
references.pmid: 26116538
references.citation: Clin Cancer Res. 2010 Oct 1;16(19):4688-94
references.pmid: 20713493
references.citation: Mol Biol (Mosk). 2014 Mar-Apr;48(2):232-42
references.pmid: 25850292
references.citation: Cancer Res. 2009 Jun 1;69(11):4851-60
references.pmid: 19487295
references.citation: Biomed Res Int. 2015;2015:125094
references.pmid: 25874201
references.citation: Oncotarget. 2015 Mar 20;6(8):6092-104
references.pmid: 25714029
references.citation: Tumour Biol. 2015 May;36(5):3129-36
references.pmid: 25809705
references.citation: Carcinogenesis. 2014 Sep;35(9):2074-83
references.pmid: 24858205
references.citation: DNA Cell Biol. 2011 Jun;30(6):401-6
references.pmid: 21345130
references.citation: Tumori. 2005 May-Jun;91(3):248-52
references.pmid: 16206649
references.citation: Onco Targets Ther. 2014 Aug 21;7:1481-5
references.pmid: 25187728
references.citation: J Hematol Oncol. 2013;6:16
references.pmid: 23406679
references.citation: Int J Cancer. 2011 Dec 1;129(11):2600-10
references.pmid: 21960261
references.citation: Oncogene. 2015 Nov 26;34(48):5857-68
references.pmid: 25867073
references.citation: BMC Res Notes. 2013;6:491
references.pmid: 24279768
references.citation: Lung Cancer. 2010 Feb;67(2):170-6
references.pmid: 19446359
references.citation: J Clin Oncol. 2011 Sep 20;29(27):3659-68
references.pmid: 21859993
references.citation: Front Biosci. 2006;11:1388-413
references.pmid: 16368524
references.citation: Lancet. 2003 Mar 8;361(9360):859-64
references.pmid: 12642065
references.citation: Eur J Cancer. 2010 Mar;46(4):765-81
references.pmid: 20116997
references.citation: Int J Clin Exp Med. 2015 Apr 15;8(4):5329-39
references.pmid: 26131109
references.citation: Tumour Biol. 2015 Sep;36(9):7069-75
references.pmid: 25869877
references.citation: CA Cancer J Clin. 2013 Jan;63(1):11-30
references.pmid: 23335087
references.citation: Int J Cancer. 2010 Jul 15;127(2):394-403
references.pmid: 19585579
references.citation: J Urol. 2005 Apr;173(4):1061-2
references.pmid: 15758699
references.citation: Cancer Cell Int. 2015 May 06;15:49
references.pmid: 25969668
references.citation: BMJ. 2013;346:f325
references.pmid: 23360718
references.citation: Int J Cancer. 2009 Dec 1;125(11):2737-43
references.pmid: 19521961
references.citation: Clin Genitourin Cancer. 2015 Aug;13(4):261-70
references.pmid: 25733057
references.citation: Am J Cancer Res. 2015 May 15;5(6):2056-63
references.pmid: 26269764